PRESS RELEASE
Results of 2021 Annual General Meeting and Board Appointment
Guildford, UK - 10 June 2021: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, announces that all resolutions put to shareholders at its Annual General Meeting ('AGM') held earlier today were passed by way of a poll.
The full text of the resolutions can be found in the Notice of Annual General Meeting on the Company's website www.ergomedplc.com.
Further to the Company's announcement on 10 May 2021, Mark Enyedy was appointed to the Company's Board of Directors as a Non-Executive Director with effect from closing of the AGM.
ENDS
Enquiries:
| Ergomed plc | Tel: +44 (0) 1483 402 975 |
| Miroslav Reljanović (Executive Chairman) | |
| Richard Barfield (Chief Financial Officer) | |
| | |
| Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
| Freddie Barnfield / Matthew O'Dowd (Nominated Adviser) | |
| James Black (Broker) | |
| | |
| Consilium Strategic Communications | Tel: +44 (0) 20 3709 5700 |
| Chris Gardner / Matthew Neal | ergomed@consilium-comms.com |
| Angela Gray
| |
| | |
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand and a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO). For further information, visit: http://ergomedplc.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
